China Biotech Services Holdings (HKSE:08037) Forward Dividend Yield % : 0.00% (As of Jun. 01, 2024)

View and export this data going back to 2004. Start your Free Trial

What is China Biotech Services Holdings Forward Dividend Yield %?

As of today (2024-06-01), the Forward Annual Dividend Yield of China Biotech Services Holdings is 0.00%.

As of today (2024-06-01), the Trailing Annual Dividend Yield of China Biotech Services Holdings is 2.99%.

HKSE:08037's Forward Dividend Yield % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.51
* Ranked among companies with meaningful Forward Dividend Yield % only.

China Biotech Services Holdings's Dividends per Share for the three months ended in Dec. 2023 was HK$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of China Biotech Services Holdings's Forward Dividend Yield %

For the Diagnostics & Research subindustry, China Biotech Services Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Biotech Services Holdings's Forward Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where China Biotech Services Holdings's Forward Dividend Yield % falls into.

China Biotech Services Holdings Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

China Biotech Services Holdings (HKSE:08037) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

China Biotech Services Holdings Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of China Biotech Services Holdings's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biotech Services Holdings (HKSE:08037) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

255-257 Gloucester Roaad, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG

Website

http://www.cbshhk.com

China Biotech Services Holdings Ltd is an investment holding company. It operates through six segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Securities, Insurance brokerage, BNCT and Others. It derives prime revenue from the Medical and health related services segment which involves the provision of medical laboratory testing and health check services. The group has a business presence in Hong Kong and the PRC, of which key revenue is generated from Hong Kong.

Executives

Liu Xiaolin	2101 Beneficial owner
Genius Earn Limited	2201 Interest of corporation controlled by you
Genius Lead Limited	2101 Beneficial owner
Guoyuan International Holdings Limited	2201 Interest of corporation controlled by you
Guoyuan Securities Co., Ltd.	2201 Interest of corporation controlled by you
Guoyuan Securities Investment (hong Kong) Limited	2101 Beneficial owner
Richlane Ventures Limited	2101 Beneficial owner
Ko Chun Shun, Johnson	2201 Interest of corporation controlled by you

China Biotech Services Holdings (HKSE:08037) Headlines

No Headlines